Efficacy of FOLFIRI plus bevacizumab versus FOLFIRI plus cetuximab in RAS-mutant metastatic colorectal cancer: Final update on patients with RAS-mutant metastatic colorectal cancer treated in FIRE-3

被引：0
|
作者：
Weiss, Lena
Stintzing, Sebastian
Modest, Dominik Paul
von Weikersthal, Ludwig
Decker, Thomas
Kiani, Alexander
Vehling-Kaiser, Ursula
Al-Batran, Salah-Eddin
Heintges, Tobias
Lerchenmuller, Christian A.
Kahl, Christoph
Seipelt, Gernot
Kullmann, Frank
Moehler, Markus H.
Scheithauer, Werner
Held, Swantje
Miller-Phillips, Lisa
Stahler, Arndt
Jung, Andreas
Heinemann, Volker
机构：
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[2] Charit Univ Med Berlin, Hematol Oncol & Canc Immunol CCM, Berlin, Germany
[3] Charite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany
[4] Gesundheitszentrum St Marien GmbH, Amberg, Germany
[5] Onkol Ravensburg, Ravensburg, Germany
[6] Klinikum Bayreuth GmbH, Dept Hematol & Oncol, Bayreuth, Germany
[7] Comprehens Canc Ctr EMN, Erlangen, Germany
[8] Practice Med Oncol, Landshut, Germany
[9] Univ Canc Ctr Germany, Frankfurt Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany
[10] Stadtische Kliniken Neuss, Neuss, Germany
[11] Hamatolog Onkolog, Greven, Germany
[12] Klinikum Magdeburg, Dept Hematol, Magdeburg, Germany
[13] Onkolog Schwerpunktpraxis, Dreieich, Germany
[14] Klinikum Weiden, Dept Med 1, Weiden, Germany
[15] Johannes Gutenberg Univ Clin, Mainz, Germany
[16] Med Univ Vienna, Vienna, Austria
[17] Clinassess Inc, Leverkusen, Germany
[18] Univ Munich, LMU Klinikum, Munich, Germany
[19] Charit Univ Med Berlin, Berlin, Germany
[20] Free Univ Berlin, Berlin, Germany
[21] Humboldt Univ, Berlin, Germany
[22] Dept Hematol Oncol & Canc Immunol, Berlin, Germany
[23] Univ Munich, Inst Pathol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3550
引用
收藏
页数：1
相关论文
共 50 条
  • [31] COST EFFECTIVENESS OF BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN TREATMENT OF ADVANCED METASTATIC COLORECTAL CANCER IN THE REPUBLIC OF KOREA
    Lee, Eui-Kyung
    Revil, Cedric
    Ngoh, Charles
    Lister, Johanna
    Kwon, Jeongmi
    Park, Meehye
    Park, Seokjin
    Park, Youngsuk
    Shin, Sangjoon
    Lee, Myungah
    Lee, Namsu
    Zang, Dae Young
    Bae, Eunjin
    Kang, Mijeong
    ANNALS OF ONCOLOGY, 2011, 22 : v125 - v125
  • [32] Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
    Holch, J. W.
    Ricard, I.
    Stintzing, S.
    von Weikersthal, L. Fischer
    Decker, T.
    Kiani, A.
    Vehling-Kaiser, U.
    Heintges, T.
    Kahl, C.
    Kullmann, F.
    Scheithauer, W.
    Moehler, M.
    Jelas, I.
    Modest, D. P.
    Westphalen, C. B.
    von Einem, J. C.
    Michl, M.
    Heinemann, V.
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 115 - 125
  • [33] Cost-effectiveness of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study
    Stintzing, Sebastian
    van Oostrum, Ilse
    Pescott, Chris P.
    Ronga, Philippe
    Heeg, Bart
    Heinemann, Volker
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 448 - 455
  • [34] Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
    Stintzing, S.
    Miller-Phillips, L.
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Kiani, A.
    Vehling-Kaiser, U.
    Al-Batran, S-E.
    Heintges, T.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Stauch, M.
    Scheithauer, W.
    Held, S.
    Moehler, M.
    Jagenburg, A.
    Kirchner, T.
    Jung, A.
    Heinemann, V.
    EUROPEAN JOURNAL OF CANCER, 2017, 79 : 50 - 60
  • [35] Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Juergen
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Schaefer, Britta
    Modest, Dominik Paul
    Jung, Andreas
    Stintzing, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [36] Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab
    Al-Shamsi, Humaid O.
    Al Farsi, Abdulaziz
    Anjum, Mahraz
    Shen, Hua
    Zbuk, Kevin
    Cook, Richard J.
    Linkins, Lori-Ann
    Major, Pierre
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (03) : 274 - 279
  • [37] Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment
    Huang, Ching-Wen
    Yeh, Yung-Sung
    Ma, Cheng-Jen
    Tsai, Hsiang-Lin
    Chen, Chao-Wen
    Huang, Ming-Yii
    Lu, Chien-Yu
    Wu, Jeng-Yih
    Wang, Jaw Yuan
    CHEMOTHERAPY, 2017, 62 (01) : 80 - 84
  • [38] FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
    Volker Heinemann
    Ludwig Fischer von Weikersthal
    Thomas Decker
    Alexander Kiani
    Florian Kaiser
    Salah-Edin Al-Batran
    Tobias Heintges
    Christoph Lerchenmüller
    Christoph Kahl
    Gernot Seipelt
    Frank Kullmann
    Markus Moehler
    Werner Scheithauer
    Swantje Held
    Lisa Miller-Phillips
    Dominik Paul Modest
    Andreas Jung
    Thomas Kirchner
    Sebastian Stintzing
    British Journal of Cancer, 2021, 124 : 587 - 594
  • [39] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Ueno, Masashi
    Yamamoto, Noriko
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
  • [40] Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
    Tomoyasu Yoshihiro
    Hitoshi Kusaba
    Akitaka Makiyama
    Kazuma Kobayashi
    Masato Uenomachi
    Mamoru Ito
    Yasuhiro Doi
    Kenji Mitsugi
    Tomomi Aikawa
    Kotoe Takayoshi
    Taito Esaki
    Hozumi Shimokawa
    Kenji Tsuchihashi
    Hiroshi Ariyama
    Koichi Akashi
    Eishi Baba
    International Journal of Clinical Oncology, 2019, 24 : 508 - 515
12345